New scan could predict liver cancer treatment success
NCT ID NCT07116486
Summary
This early-phase study is testing whether a special PET scan (using a tracer called 18F-FSPG) and blood tests can predict how well liver cancer patients will respond to Y90 radioembolization treatment. Researchers will enroll 60 patients with hepatocellular carcinoma who are already scheduled to receive Y90 therapy. The goal is to see if these new tests can detect treatment response earlier than standard imaging methods.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.